Effects of Bupropion Augmentation in Escitalopram-Resistant Patients With Major Depressive Disorder: An Open-Label, Naturalistic Study

View This PDF

NB: This article is only available as a PDF.

Letter to the Editor

Sir: There is a pressing need for improvement of treatment response to antidepressants in depression. Increasing evidence shows that bupropion, a norepinephrine and dopamine reuptake inhibitor, is one of the most widely chosen and effective augmenting agents for depressive patients with insufficient response to serotonin reuptake inhibitors. In this study, we evaluated the efficacy and tolerability of bupropion augmentation in nonresponders to escitalopram monotherapy in order to better understand this potential approach to improving treatment outcome in depression.

J Clin Psychiatry 2009;70(7):1054-1056